Meetings

The Estée Lauder Companies Inc. (NYSE: EL) research and development (R&D) team will present data that provides new insights in priority areas of research including epidermal function and skin barrier, fermentation, skin aging and pigmentation. The Estée Lauder Companies’ R&D team is a global leader in understanding the factors that impact our skin, with R&D playing a key role in gathering insights on how the skin appears and behaves. Scientists from the Estée Lauder Companies R&D and brand research teams will present their latest findings at the 2022 Society for Investigative Dermatology (SID) Annual Meeting in Portland, Oregon, from May 18-21. The SID Annual Meeting is a top dermatology conference that allows an expansive community of scientists and researchers to share the latest advancements in the skin care field.

Avacopan was better than prednisone in reducing respiratory as well as ear, nose and throat (ENT) involvement and enabled reduced glucocorticoid use in ANCA-associated vasculitis patients participating in the phase 3 ADVOCATE trial. Study results were published at the ATS 2022 international conference. The study was a subgroup analysis of results from the larger trial, which led to FDA approval of avacopan.

One of the legacies of “redlining” may be higher incidence and mortality rates of COVID-19 affecting the largely minority and poor residents of these neighborhoods, according to research published at the ATS 2022 international conference. ” Redlining is a Great Depression-era federal policy in which neighborhoods with large ethnic/racial minority groups were denied federal resources.

May 17, 2022 – People living with schizophrenia and other psychosis spectrum disorders are too often misunderstood or ignored – by the public, by the healthcare system – and current treatments are outdated and often cause significant side effects. On Nov. 2, the schizophrenia community will finally have the spotlight, as those living with the condition and their family members share their treatment needs and concerns with drug developers and FDA staff who review new drug applications. The Externally-Led Patient Focused Drug Development (PFDD) meeting – “Reimagine Schizophrenia: Transforming How We Are Treated, Function and Thrive” – offers the chance to make what matters to those living with the neurobiological brain disease a higher priority in drug development and the FDA review process.

Paris, France. 17 May 2022. May 17th is World Hypertension Day whose theme “Measure Your Blood Pressure Accurately, Control It, Live Longer” is aimed at increasing awareness of hypertension worldwide. Besides awareness, effective control of hypertension remains low in the general population. At EuroPCR 2022, the Global SYMPLICTY Registry and 3 ongoing trials – SPYRAL-HTN ON MED, RADIANCE-HTN SOLO and TRIO – will further focus on expanding experience in effective device-based treatments for hypertension using renal denervation.

At the Science7 Dialogue Forum in Berlin/Germany on Tuesday, 31 May, the science academies of the G7 states will publish science-based statements on topics on this year's agenda of the G7 summit at Schloss Elmau/Germany. Key topics of the statements prepared under the leadership of the Leopoldina are the effects of climate change on polar regions and ocean, measures for decarbonisation, the development of antiviral drugs for pandemic preparedness and the need for a One Health approach to address zoonoses and antimicrobial resistance. Representatives of the national science academies will hand over the statements to the German government during the Science7 Dialogue Forum. Media representatives are invited to attend the event and the associated science conference. Prior registration is required.

A greater proportion of patients with severe, uncontrolled asthma had more significant clinical responses to tezepelumab than placebo, according to research published at the ATS 2022 international conference. The study showed that nearly half of those enrolled achieved complete response to treatment across measures of exacerbation reduction, asthma control, lung function, and clinician assessment.